Showing results (201-210 of 255) with videos related to
Sort By:
Pageof 26
European Heart Journal|March 4, 2026
Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term studyAlbree Tower-Rader, Ahmad Masri, Michael E Nassif, et al.Journal of the American College of Cardiology|May 20, 2021
Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HFJohn R Teerlink, Rafael Diaz, G Michael Felker, et al.Journal of Medicinal Chemistry|October 12, 2021
Discovery of Reldesemtiv, a Fast Skeletal Muscle Troponin Activator for the Treatment of Impaired Muscle FunctionScott E Collibee, Gustave Bergnes, Chihyuan Chuang, et al.Journal of the American College of Cardiology|September 1, 2024
Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM CMR SubstudyAhmad Masri, Rhanderson N Cardoso, Theodore P Abraham, et al.JACC. Heart Failure|March 7, 2023
Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction: Insights From GALACTIC-HFDavid E Lanfear, Joyce N Njoroge, Kirkwood F Adams, et al.Cardiovascular Drugs and Therapy|July 24, 2017
Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics ConferenceThomas J Povsic, Rob Scott, Kenneth W Mahaffey, et al.Circulation. Heart Failure|November 8, 2025
Effect of Aficamten in Women Compared with Men with Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCMXiaowen Wang, Maria A Pabon, Tracy T Makuvire, et al.Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 24, 2021
Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating StudyStacy A Rudnicki, Jinsy A Andrews, Tina Duong, et al.Journal of the American College of Cardiology|October 30, 2024
Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCMAhmad Masri, Lubna Choudhury, Roberto Barriales-Villa, et al.Journal of the American College of Cardiology|September 1, 2024
Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic CardiomyopathySheila M Hegde, Brian L Claggett, Xiaowen Wang, et al.Pageof 26